KR940003552A - 지방산을 이용한 석회화 예방 및 치료방법 - Google Patents
지방산을 이용한 석회화 예방 및 치료방법 Download PDFInfo
- Publication number
- KR940003552A KR940003552A KR1019930016203A KR930016203A KR940003552A KR 940003552 A KR940003552 A KR 940003552A KR 1019930016203 A KR1019930016203 A KR 1019930016203A KR 930016203 A KR930016203 A KR 930016203A KR 940003552 A KR940003552 A KR 940003552A
- Authority
- KR
- South Korea
- Prior art keywords
- acid
- prevention
- treatment
- day
- fatty acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Fats And Perfumes (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
본 발명은 인체 또는 동물체내 조직의 변위석회화의 예방 및/또는 치료에 관한 것으로, 감마-리놀렌산(GLA) 및,/또는 그 필수지방산 (EFA) 대사물질을 투여하고, 특히 급속히 생 성된 디호모-감마-리놀렌산 (DGLA) 및/또는 에이코사펜타에논산 (EPA) 및/또는 그 전구물, 스테아리돈산과 20:4n-3 및 대사물질, 도코사헥사에논산 (DHA) 또는 도코사펜타에논산 (22:5n-3)을 함게 투여하며, 이들은 그 자체로 투여되거나 또는 염이나 약리학적으로 허용되는 형태로 투여된다. 본 발명은 특히 신장석회증 및/또는 신장결석의 예방이나 치료에 적합하다.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (10)
- 감마-리놀렌산(GLA) 및/또는그 필수지방산(EFA) 대사물질을 투여하고, 특히 급속히 생성된 디호모-감마-리놀렌사 (DGLA) 및/또는 에 이코 사펜타에논산 (EPA) 및/또는 그 전구물, 스테아리돈산과 20 : 4 n-3 및 대사 물질. 도코사헥사에논산(OHA) 또는 도코사펜타에논산 (22's n-3)을 함께 투여하고, 여기서, 필수지방산 은 염 이나 약리학적으로 허용되는 형태로 투여됨을 특징으로 하는 인체 또는 동물체 내 조직의 변위석회화를 치료하거나 예방하기 위한 방법.
- 제1항에 있어서, 신장석회중 및,/또는 신장결석의 치료나 예방에 적용됨을 특징으로 하는 방법.
- 제1항에 있어서, 혈관, 각막, 결막, 피부 및 뇌를 포함하는 연질 조직내 변위석회화의 치료나예방을 특징으로 하는 방법.
- 제1항 내지 제3항 중 어느 한 항에 있어서, 각 필수지방산은 0.01∼1,000mg/kg/1일, 바람직하게는 0.5∼50mg/kg/1일, 더욱 바람직하게는 2-30mg/kg/1일의 용량으로 투여됨을 특징으로 하는 방법.
- 제4항에 있어서, 지방산은 단위재형의 형태로 투여됨을 특징으로 하는 방법.
- 인체 또는 동물체내 조직의 변위석회화를 치료하거나 예방하기 위한 의약제조에 있어서, 그대로의 형태 또는 염 또는 다른 약리학적으로 허용되는 형태의 감마-리놀렌산(GLA) 및/또는 그 필수지방산(EFA) 대사물질, 및 특히 급속히 생성된 디호모-감마-리놀렌사(DGLA)의 용도, 및/또는 그대로의 형태 또는 염 또는 약리학적으로 허용되는 헝태의 에이코사펜타에논산 (EPA) 및/또는 그 전구물, 스테아리돈산과 27:4n-3, 및 대사 물질, 도코사헥사에논산 (DHA) 또는 도코사펜타에논산 (22:5n-3)의 용도.
- 제6항에 있어서, 의약은 투여에 적합한 각 필수지방산을 0.01∼1, O0mg/kg/1일, 바람직하게는 0.5∼100mg/kg/일, 보다 바랑직하게는 2∼30mg/kg/1일의 양으로 함유함을 특징으로 하는 용도.
- 제6항 또는 제7항에 있어서, 의약은 단위제형의 형태로 제시됨을 특징으로 하는 용도.
- 제6항에 있어서, 의약은 혈관, 각막, 결막, 피부 및 뇌를 포함하는 연질조직내 변위석회화의 치료나 예방을 위해 사용되는 것을 특징으로 하는 용도.
- 제6항 내지 제9항 중 어느 한 항에 있어서, 의약은 신장석회중 및/또는 신장결석의 치료나 예방을 위한 것임을 특징으로 하는 용도.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB929217781A GB9217781D0 (en) | 1992-08-21 | 1992-08-21 | Fatty acid treatment |
GB9217781.5 | 1992-08-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
KR940003552A true KR940003552A (ko) | 1994-03-12 |
Family
ID=10720717
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019930016203A KR940003552A (ko) | 1992-08-21 | 1993-08-21 | 지방산을 이용한 석회화 예방 및 치료방법 |
Country Status (17)
Country | Link |
---|---|
EP (1) | EP0585027B1 (ko) |
JP (1) | JPH06172169A (ko) |
KR (1) | KR940003552A (ko) |
CN (1) | CN1090490A (ko) |
AT (1) | ATE164518T1 (ko) |
AU (1) | AU666748B2 (ko) |
CA (1) | CA2104566A1 (ko) |
DE (1) | DE69317716T2 (ko) |
DK (1) | DK0585027T3 (ko) |
ES (1) | ES2117104T3 (ko) |
GB (1) | GB9217781D0 (ko) |
GR (1) | GR3026708T3 (ko) |
MY (1) | MY131357A (ko) |
NO (1) | NO932984L (ko) |
NZ (1) | NZ248451A (ko) |
RU (1) | RU2122408C1 (ko) |
ZA (1) | ZA936133B (ko) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2119000A1 (en) * | 1993-03-19 | 1994-09-20 | David Frederick Horrobin | Formulation for use in smokers |
US5668174A (en) * | 1993-12-29 | 1997-09-16 | Kowa Tekuno Sachi Co., Ltd. | Method of treating hyperparathyroidism |
AU693312B2 (en) * | 1995-01-18 | 1998-06-25 | Taisho Pharmaceutical Co., Ltd. | Remedy for dermatitis |
GB9617847D0 (en) | 1996-08-27 | 1996-10-09 | Scotia Holdings Plc | Fatty acid treatment |
JP4607264B2 (ja) * | 1998-12-01 | 2011-01-05 | 生化学工業株式会社 | ヒアルロン酸を有効成分とする異所性石灰化抑制剤 |
AU2002318135B2 (en) * | 2001-05-14 | 2007-08-02 | Dsm Ip Assets B.V. | Production and use of a polar lipid-rich fraction containing stearidonic acid and gamma linolenic acid from plant seeds and microbes |
FR2839887A1 (fr) | 2002-05-22 | 2003-11-28 | Synergia | Nouvelles compositions nutraceutiques et pharmaceutiques et leurs utilisations |
JP4575105B2 (ja) * | 2004-10-07 | 2010-11-04 | ポリエン・プロジェクト有限会社 | 骨芽細胞活性抑制剤 |
CN103202483A (zh) * | 2012-01-11 | 2013-07-17 | 浙江康恩贝健康产品有限公司 | 一种补钙营养组合物 |
CA2916208A1 (en) | 2012-06-17 | 2013-12-27 | Matinas Biopharma, Inc. | Omega-3 pentaenoic acid compositions and methods of use |
MX2018014140A (es) * | 2016-06-01 | 2019-02-25 | Nestec Sa | Composicion para usar en la profilaxis de enfermedades alergicas. |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3474633D1 (en) * | 1984-02-01 | 1988-11-24 | Tpo Pharmachim | Means for the treatment and the prophylaxis of uratic and mixed uratic lithiasis |
CA1302879C (en) * | 1986-05-02 | 1992-06-09 | Vicki E. Kelley | Composition having reduced nephrotoxicity comprising a fatty acid containing component and cyclosporine |
GB9112052D0 (en) * | 1991-06-05 | 1991-07-24 | Efamol Holdings | Fatty acid treatment |
-
1992
- 1992-08-21 GB GB929217781A patent/GB9217781D0/en active Pending
-
1993
- 1993-08-16 ES ES93306445T patent/ES2117104T3/es not_active Expired - Lifetime
- 1993-08-16 EP EP93306445A patent/EP0585027B1/en not_active Expired - Lifetime
- 1993-08-16 DE DE69317716T patent/DE69317716T2/de not_active Expired - Fee Related
- 1993-08-16 AT AT93306445T patent/ATE164518T1/de not_active IP Right Cessation
- 1993-08-16 DK DK93306445.3T patent/DK0585027T3/da active
- 1993-08-20 NZ NZ248451A patent/NZ248451A/en unknown
- 1993-08-20 CA CA002104566A patent/CA2104566A1/en not_active Abandoned
- 1993-08-20 RU RU93049092A patent/RU2122408C1/ru active
- 1993-08-20 ZA ZA936133A patent/ZA936133B/xx unknown
- 1993-08-20 JP JP5206165A patent/JPH06172169A/ja active Pending
- 1993-08-20 AU AU44748/93A patent/AU666748B2/en not_active Ceased
- 1993-08-20 NO NO932984A patent/NO932984L/no unknown
- 1993-08-21 CN CN93118321A patent/CN1090490A/zh active Pending
- 1993-08-21 MY MYPI93001673A patent/MY131357A/en unknown
- 1993-08-21 KR KR1019930016203A patent/KR940003552A/ko not_active Application Discontinuation
-
1998
- 1998-04-23 GR GR980400896T patent/GR3026708T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
ATE164518T1 (de) | 1998-04-15 |
AU4474893A (en) | 1994-02-24 |
DE69317716D1 (de) | 1998-05-07 |
MY131357A (en) | 2007-08-30 |
GR3026708T3 (en) | 1998-07-31 |
JPH06172169A (ja) | 1994-06-21 |
CN1090490A (zh) | 1994-08-10 |
EP0585027B1 (en) | 1998-04-01 |
RU2122408C1 (ru) | 1998-11-27 |
AU666748B2 (en) | 1996-02-22 |
GB9217781D0 (en) | 1992-10-07 |
DE69317716T2 (de) | 1998-09-17 |
NZ248451A (en) | 1997-07-27 |
DK0585027T3 (da) | 1998-05-11 |
ZA936133B (en) | 1994-03-17 |
ES2117104T3 (es) | 1998-08-01 |
NO932984D0 (no) | 1993-08-20 |
CA2104566A1 (en) | 1994-02-22 |
NO932984L (no) | 1994-02-22 |
EP0585027A1 (en) | 1994-03-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR940003553A (ko) | 지방산을 함유하는 조성물 및 지방산을 이용한 처지방법 | |
US6624195B2 (en) | Pharmaceutical preparation comprising eicosapentaenoic acid and/or stearidonic acid | |
AU618814B2 (en) | Essential fatty acid compositions | |
US5888541A (en) | Fatty acid treatment | |
KR20030016306A (ko) | 지방산의 치료용 조합 | |
HU226673B1 (en) | Use of essential fatty acids and bioactive disulphides for the preparation of therapeutic and dietary compositions | |
KR940018089A (ko) | 내부조직의 방사선 손상에 대한 예방 및 처치방법 | |
KR920000324A (ko) | 필수 지방산 처리법 | |
JP2000517339A (ja) | 脂肪酸による治療 | |
KR940003552A (ko) | 지방산을 이용한 석회화 예방 및 치료방법 | |
KR930000114A (ko) | 지방산을 이용한 치료 | |
US5516801A (en) | Fatty acid treatment for ectopic calcium deposition | |
AU667937B2 (en) | Method for the safe administration of fatty acid | |
EP0402208B1 (fr) | Association de vitamine A à dose physiologique et de différents principes actifs ayant une activité thérapeutique | |
RU99106551A (ru) | Применение арахидоновой кислоты и/или докозагексаеновой кислоты для получения лекарства для лечения диспраксии | |
KR940008688A (ko) | 필수지방산에 의해 킬레이트화된 아연정제 | |
MXPA99003365A (es) | Preparacion farmaceutica que comprende acido eicosapentaenoico y/o acido estearidonico | |
MXPA00000793A (en) | Therapeutic and dietary compositions containing essential fatty acids and bioactive disulphides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E601 | Decision to refuse application |